NEW YORK (GenomeWeb News) – Molecular diagnostics firm PrimeraDx today announced a deal with Eli Lilly to develop diagnostics in support of the drug firm's therapeutic development programs.

The multiyear deal calls for the two firms to collaborate on the development of multiplex assays on PrimeraDx's ICEPlex System, an automated, high-throughput real-time PCR and capillary electrophoresis instrument. Financial and other terms of the deal were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.